RISPERDAL CONSTA

Compare RISPERDAL CONSTA  to:
Compare
Compare

Generic Name for RISPERDAL CONSTA

Risperidone 12.5mg, 25mg, 37.5mg, 50mg; per vial; pwd for long-acting IM inj after reconstitution.

Legal Classification:

Rx

Pharmacological Class for RISPERDAL CONSTA

Benzisoxazole.

Manufacturer of RISPERDAL CONSTA

Janssen Pharmaceutica Products, LP

Indications for RISPERDAL CONSTA

Schizophrenia.

Adult dose for RISPERDAL CONSTA

Risperidone-naive: rule out risperidone hypersensitivity before using injection. Give by deep deltoid or gluteal IM inj; alternate sides. Give with oral risperidone (or other antipsychotic) for 3 weeks, then stop oral form. ≥18yrs: 25mg IM every 2 weeks; may adjust dose every 4 weeks. Max 50mg every 2 weeks. Renal or hepatic impairment: if total daily dose of at least 2mg of oral risperidone tolerated, may give 12.5mg or 25mg IM every 2 weeks. History of poor tolerability to psychotropic drugs or drug interactions that increase risperidone plasma levels (see literature): may use lower initial dose of 12.5mg.

Children's dosing for RISPERDAL CONSTA

<18yrs: not recommended.

Also:

Warnings/Precautions for RISPERDAL CONSTA

Diabetes risk factors (obtain baseline fasting blood sugar). Monitor for hyperglycemia. Cardio- or cerebrovascular disease. Renal or hepatic dysfunction. Orthostatic hypotension. Pre-existing low WBC count or history of leukopenia/neutropenia: monitor CBC during 1st few months of therapy; discontinue if WBCs decline. Parkinson's disease. Dementia with Lewy bodies. Diseases that affect metabolic or hemodynamic response. History of breast cancer or seizures. Dysphagia. Reevaluate periodically. Monitor for neuroleptic malignant syndrome. May have antiemetic effect. Exposure to extreme temperatures. Suicidal patients. Elderly (not for dementia-related psychosis); consider monitoring renal function and for orthostatic effects. Pregnancy (Cat.C). Nursing mothers: not recommended (do not breastfeed until at least 12 weeks after last injection).

Interactions for RISPERDAL CONSTA

Avoid alcohol. Caution with other CNS drugs. May potentiate antihypertensives. May antagonize levodopa, dopamine agonists. Clearance may be decreased by clozapine; may be increased by carbamazepine, other enzyme inducers (eg, phenytoin, rifampin, phenobarbital); adjust risperidone dose. May be potentiated by cimetidine, ranitidine. May be affected by fluoxetine, paroxetine, others that affect CYP isoenzymes. Monitor valproate.

Adverse Reactions for RISPERDAL CONSTA

Headache, somnolence, increased appetite, fatigue, rhinitis, upper respiratory tract infection, vomiting, coughing, urinary incontinence, increased saliva, constipation, fever, parkinsonism, dystonia, abdominal pain, anxiety, GI upset, dizziness, dry mouth, tremor, rash, akathisia; orthostatic hypotension, tardive dyskinesia, neuroleptic malignant syndrome, hyperprolactinemia, priapism, leukopenia/neutropenia, agranulocytosis, thrombotic thrombocytopenic purpura (rare).

How is RISPERDAL CONSTA supplied?

Inj: single-use vial—1 (pack w. diluent, supplies)
Tabs 0.25mg, 0.5mg, 1mg, 2mg, 3mg—60, 500
4mg—60
Oral soln—30mL (w. pipette)
M-Tabs—28

Related Disease:

Schizophrenia

Related Resources

Phase 3 study of pimavanserin for the treatment of Parkinson's disease psychosis (PDP)

July 29, 2010

Acadia Pharmaceuticals announced the initiation of its Phase 3 study of pimavanserin for the treatment of Parkinson's disease psychosis (PDP).

FDA launches "Bad Ad Program" to detect misleading drug ads

May 11, 2010

The FDA's Division of Drug Marketing, Advertising, and Communications (DDMAC) has launched the Bad Ad Program, designed to educate healthcare providers about their role in ensuring that prescription drug advertising and promotion is truthful, and not misleading.

FDA accepts NDA for lurasidone, a treatment for schizophrenia

March 11, 2010

Dainippon Sumitomo Pharma America announced that the FDA has accepted for filing the New Drug Application (NDA) submitted for lurasidone for the treatment of schizophrenia.

Zyprexa Prescribing Information updated for use in adolescents

February 01, 2010

Lilly and the FDA had notified healthcare professionals of changes to the Prescribing Information for Zyprexa (olanzapine) related to its indication for use in adolescents (13-17 years of age) for the treatment of schizophrenia and bipolar I disorder.

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions